Objectives: Aspergillus spp. (Asp) or Candida spp. (CA) isolation from sputum samples in CF children is common, but with yet unclear significance. We studied Asp and CA isolation from respiratory secretions in CF children and their effect on lung function and hospitalizations. Methods: 8-year retrospective cohort study of 121 CF children (3,601 sputum samples). Isolation was defined as the presence of at least one positive culture. Multiple regressions assessed the effect on spirometry results and hospitalizations on study completion after adjustment for 10 confounders whereas simple comparisons were also performed. Asp (33.1%) was associated with genotype (p = 0.041), BMI (p = 0.037), pancreatic insufficiency (p = 0.005), ABPA (p = 0.006), pos corticosteroids >3months (p = 0.038), pos antifungal (p < 0.001), azithromycin (p = 0.021) and rhDNase (p = 0.008). CA (71.1%) was associated with weight (p = 0.042), pancreatic insufficiency (p < 0.001), CFRD (p = 0.040), ABPA (p = 0.003), P. aeruginosa colonization (p = 0.006), Asp (p = 0.005), pos corticosteroids >3months (p < 0.001), inh corticosteroids >3months (p = 0.030), pos antifungal (p = 0.006) and rhDNase (p = 0.017). Asp was associated with FVC %predicted (b = −11.739, SE = 5.737, p = 0.045), FEV 1 %predicted (b = −14.734, SE = 6.598, p = 0.029) and hospitalizations (b = 2.458, SE = 0.916, p = 0.009) after adjustment for confounders while CA wasn't. But, there was a trend toward significance for hospitalizations (b = 2.230, SE = 1.200, p = 0.068). Conclusions: Asp in respiratory secretions in CF children is associated with a decline in lung function and an increase in hospitalizations while CA tends to increase hospitalizations.
Wildtype clinical and reference bacterial isolates are an extremely important asset and resource for academic clinicians and researchers within CF. Our historical experience is that physical isolate/strain repositories (both CF and others) are expensive and difficult to maintain and manage. Sufficient resource already exists within National Reference Collections of organisms throughout Europe including CRBIP, Institute Pasteur (France), BCCM (Belgium), CBS (The Netherlands), DSMZ (Germany), IST (Italy) and the National Collection of Type Cultures (UK) for the provision of Reference/Type CF strains. To date, provision of wildtype clinical isolates resides with clinical microbiology in hospitals serving European CF Centres and are not well characterised in any consolidated manner, resulting in an ad hoc collection of isolates throughout Europe with poor visability and exploitability. CF MicroARK has established an on-line resource hosted at the CF Association of Ireland website (www.cfireland.ie) for the benefit of CF researchers in Ireland, Europe and beyond. The project has e-captured all available wildtype isolates that physically exists in culture archives at CF centres throughout the Island of Ireland and has catalogued these within various CF-specific databases. Ownership of the CF isolates remains with the custodians of the host laboratory, where they currently reside in a variety of laboratories and depositing laboratories have the ability to administer and update their catalogue independently. It is hoped that CF MicroARK now becomes a vibrant and dynamic gateway for the exchange of wildtype isolates within the CF research community. Introduction: Burkholderia pseudomallei has been described in patients living and visiting tropical climates and geographical differences in Pseudomonas aeruginosa have also been reported [1, 2] . The Prince Charles Hospital CF centre serves patients from an area of~1.8 million km 2 , half of which lies north of the Tropic of Capricorn where 17.9% of our patients reside. Methods: Sputum microbiology from all samples processed in the previous 10 years from patients living in tropical Australia (n = 69) was compared with those from sub-tropical regions and with data from the Australian CF Data Registry (ACFDR). The data included patients who were alive, deceased and had been transplanted as of December 2011. Results: Isolation of non-tuberculous mycobacteria (NTM) ever was elevated in tropical patients (24.6% compared with 8.2% subtropical patients, c 2 = 13, p = 0.0003 and <1% of the ACFDR). Burkholderia cepacia complex (Bcc) was reported in 17.9% of tropical patients compared with 11.1% subtropical patients (not significant) and 7.4% of the ACFDR. Isolation of Burkholderia pseudomallei was elevated in the tropical group (7.3% compared with 0.6% of the subtropical group, c 2 = 13.9, p = 0.0002). Rates of S. aureus, MRSA and P. aeruginosa were comparable to the subtropical patients and the ACFDR, however Aspergillus sp. was more commonly isolated in the tropics (53% of patients compared with 14% ACFDR). Conclusions: Patients residing in tropical Australia have higher detection rates of NTM, B. pseudomallei and Aspergillus sp than subtropical patients attending TPCH or the Australian CF population as a whole.
